Tillotts Pharma AG Celebrates 15 Years as an Integral Part of the Japanese Zeria Group

RHEINFELDEN, Switzerland, February 13, 2025 – Life Science Newswire – Tillotts Pharma AG ("Tillotts") proudly marks its 15th anniversary as a member of the Japanese Zeria Group, celebrating a period of exceptional growth and valuable collaboration together. The milestone was commemorated in December 2024 with Tillotts’ CEO, Thomas A. Tóth von Kiskér, and members of the leadership team visiting Zeria. During this special occasion, Mr. Sachiaki Ibe, Chairman of the Board of Directors and CEO of Zeria Pharmaceutical Co., Ltd., presented Mr. Tóth a symbolic piece of Japanese art featuring Mount Fuji as a gift to honor Zeria’s appreciation for Tillotts’ remarkable accomplishments since the acquisition.

Over the past 15 years, Tillotts has consistently achieved strong double-digit growth and broadened its portfolio while leveraging the trust and support of the Zeria Group. Tillotts’ remarkable success and progress is largely due to the exceptional dedication of its employees, who constantly strive to unlock the full potential of both in-house developments and in-licensed products and technologies. This commitment has also led to Tillotts in-licensing the product Dificlir™ for the treatment of Clostridioides difficile infection (CDI) in 2020, a potentially life-threatening disease. An effective and rapid integration of Dificlir™ enabled the company to quadruple its revenue since its in-licensing.
 

Mr. Sachiaki Ibe, Chairman of the Board of Directors and CEO of Zeria Pharmaceutical Co., Ltd., Mr Mitsuhiro Ibe Director of Zeria Pharmaceutical Co., and Tillotts’ CEO, Thomas A. Tóth von Kiskér (right to left) at the celebration ceremony at Zeria’s headquarters in Tokio.

Mr. Sachiaki Ibe, Chairman and CEO of Zeria Pharmaceutical Co., Ltd. said:
"Tillotts has shown extraordinary performance over these 15 years, and I sincerely appreciate the significant contributions made to the Zeria Group. Our partnership has been strengthened over the years and has positively influenced the future trajectory of both Tillotts and Zeria. I extend my sincere gratitude to the entire Tillotts team for their dedication and look forward to continued growth for both Zeria and Tillotts through our collaborative efforts", says Mr. Sachiaki Ibe.

Thomas A. Tóth, CEO of Tillotts Pharma AG, reflected:
"The long-standing partnership with Zeria fills us with great pride and gratitude for the mutual trust we have built over the years. Tillotts has evolved from a key player in IBD to a strong specialty pharma company, establishing ourselves as a leader in gastroenterology and infectious diseases. Our successes have allowed us to broaden our network of affiliates across Europe, with ambitions to grow beyond the continent in the near future. I am immensely grateful to our employees for their passion and hard work in pursuing our goal of reaching even more patients and improving their lives."

 

For more information, please contact:
Tillotts Pharma AG
Susi Teichmann
Lead Corporate Communication
Phone: +41 79 692 27 96
Email: susi.teichmann@tillotts.com

About Tillotts
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 400 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of partners throughout the world.

The rights to the trademark Asacol® are owned by Tillotts. Copyright© by Tillotts Pharma AG. All rights reserved. For more information, please visit www.tillotts.com.

About Zeria
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit www.zeria.co.jp.